 BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 GLOBE NEWSWIRE -- BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomXs atopic dermatitis product candidate, BX005, in Japan. The right of first offer will commence following the availability of results from the Phase 12 study of BX005 expected in 2022. Maruho also entered into a binding agreement for an equity investment in BiomX of 3 million at a premium to the market share price, intended primarily to support the Phase 12 study. 